ReviewClinical and translational allergy2025
20 years of the socioeconomic impact of atopic dermatitis and alopecia areata from around the globe.
Review in Clinical and translational allergy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- 20 years of the socioeconomic impact of atopic dermatitis and alopecia areata from around the globe.Clinical and translational allergy · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Atopic dermatitis (AD) and alopecia areata (AA) represent chronic inflammatory diseases characterized by heterogeneous immune-mediated mechanisms, including subtypes that may interconnect the two diseases, as well as other comorbidities. AD is globally recognized as the most common inflammatory skin disease and AA is an autoimmune disease, causing non-scarring hair loss. In both diseases the quality of life (QoL) is decreased, out-of-pocket expenses on alternative therapies and camouflage endeavours is high, increased productivity loss/absenteeism at work or school, and high healthcare costs are significant. These diseases are not life threatening but result in a substantial socioeconomic impact, which so far has been difficult to quantify on the global scale. This qualitative review that includes literature published between 2004 and 2024 evaluates the current alignment between available healthcare resources and the comprehensive needs of these patients. Currently available data indicates that the socioeconomic impact of AD and AA is evidently high, meanwhile there is data lacking from most countries in Africa, Scandinavia and East Europe, the Middle East, South Asia, and parts of Latin America. Global studies with standardized methodology are necessary to assess the socio-economic impact of these conditions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.